EP1587952B1 - Verbessertes verfahren zum nachweis von proteolytischen enzymen - Google Patents

Verbessertes verfahren zum nachweis von proteolytischen enzymen Download PDF

Info

Publication number
EP1587952B1
EP1587952B1 EP04706386A EP04706386A EP1587952B1 EP 1587952 B1 EP1587952 B1 EP 1587952B1 EP 04706386 A EP04706386 A EP 04706386A EP 04706386 A EP04706386 A EP 04706386A EP 1587952 B1 EP1587952 B1 EP 1587952B1
Authority
EP
European Patent Office
Prior art keywords
caspase
pro
protease
modified
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP04706386A
Other languages
English (en)
French (fr)
Other versions
EP1587952A2 (de
Inventor
Johan Hendrikus Verheijen
Jan Roeland Occo Hanemaaijer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Original Assignee
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO filed Critical Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Priority to EP04706386A priority Critical patent/EP1587952B1/de
Publication of EP1587952A2 publication Critical patent/EP1587952A2/de
Application granted granted Critical
Publication of EP1587952B1 publication Critical patent/EP1587952B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase

Definitions

  • the invention is in the field of determining or quantifying the activity of a proteolytic enzyme in a sample and concerns substrates, to be used therefore and an assay process and an assay kit and device therefore.
  • proteases catalyze the hydrolysis of peptide bonds in proteins or peptides. These enzymes widely occur in nature from viruses to man and have many different functions. They are involved in digestive processes both on the level of the organism (digestive tract enzymes e.g. trypsin, chymotrypsin and pepsin) and individual cells (lysosomal enzymes e.g. cathepsins).
  • digestive tract enzymes e.g. trypsin, chymotrypsin and pepsin
  • individual cells lysosomal enzymes e.g. cathepsins.
  • proteolytic enzymes play critical roles in regulatory networks such as blood coagulation, fibrinolysis, blood pressure regulation and pro hormone and growth factor processing. More recently it has been discovered that proteases play critical roles in cellular signalling and programmed cell death (apoptosis). Apart from these (patho) physiological functions proteolytic enzymes are increasingly used in biotechnology, ranging from e.g. pharmaceutical synthesis to preparation of food (e.g. cheese) and in very large scale in detergents for general and special use. Proteases can be used as pharmaceuticals themselves (e.g. plasminogen activators as thrombolytic agents) or be the target for drugs (e.g. HIV protease and angiotensin converting enzyme).
  • proteolytic enzymes catalyze the same basic reaction: i.e. a peptide bond is hydrolysed under mild conditions, typically pH between 5-8 and temperature between 25 - 40°C. Without enzyme much harsher conditions such as boiling in 6 M hydrochloric acid are required.
  • mild conditions typically pH between 5-8 and temperature between 25 - 40°C.
  • proteolytic enzymes can almost all be classified in four different classes based on the catalytic mechanism and the amino acid residues involved in catalysis (table I).
  • proteolytic enzymes having different substrate specificities and properties occur.
  • Many proteolytic enzymes are synthesised in an inactive, pro-enzyme or zymogen form. Activation, conversion of the inactive pro-enzyme form to the active proteolytic enzyme, is in most cases itself a proteolytic process. In this way positive or negative feedback regulation can occur, which is essential for proteolytic cascades like the ones occurring in blood coagulation and apoptosis.
  • proteolytic enzymes Due to their involvement in many (patho) physiological processes, proteolytic enzymes play a role in many diseases and measurement of the activity of certain proteolytic enzymes can be important for diagnosis, prognosis or to follow therapy (see Table II) .
  • the use of compounds interfering with protease activity as drugs in a variety of diseases is increasing (e.g. anticoagulants, HIV drugs).
  • This C-terminal part can be replaced by a chromogenic or fluorogenic leaving group like p-nitro-aniline (pNA), ⁇ -naphtylamine ( ⁇ NA), amino methyl coumarine (AMC) or 7-amino-4-trifluoro methyl coumarine (AFC).
  • pNA p-nitro-aniline
  • ⁇ NA ⁇ -naphtylamine
  • AMC amino methyl coumarine
  • AFC 7-amino-4-trifluoro methyl coumarine
  • the specificity and sensitivity obtained with these peptide substrates is sufficient to enable detection and quantification of physiologically relevant concentrations of proteolytic enzymes in biological fluids or tissue extracts.
  • the sensitivity can be further increased by employing two coupled reactions as has been described for plasminogen activators ( Drapier et al. (1979) Biochimie 61, 463-471 ). Similar methods can also be used for measurement of activity of cysteine proteases.
  • many peptide substrates have been developed for the caspase family of cysteine proteases involved in apoptosis.
  • substrates where a non-peptide bond is split such as the chromogenic or fluorogenic substrates used for determination of serine- or cysteine- proteases cannot be employed for determination of metalloproteases or aspartyl proteases.
  • peptides containing only the necessary recognition sequence for the protease In this case hydrolysis is followed by physico-chemical techniques like HPLC or mass spectrometry; (2) Peptides containing a sulphur containing peptide bond equivalent on the hydrolysis site. The subsequent liberation of a thiolate group is monitored by a color reagent; (3) Peptides containing besides the recognition sequence also a potential fluorescent group together with a quenching group. When both groups are in close proximity fluorescence is quenched. After hydrolysis of the cleavable peptide bond fluorescent group and quencher become separated and fluorescence is observed.
  • Assays based on principle (1) are generally elaborate, difficult to set up, require special skills and equipment, are difficult to automate and cannot easily be run in a kinetic fashion. Assays based on principles (2) and (3) are in use but have a limited sensitivity and specificity.
  • pro-enzyme is used that is modified in such a way that its normal activation recognition sequence is replaced or adapted in such a way that it can be cleaved by a protease of choice. Cleavage of this sequence results in an active enzyme that can be detected using conventional substrates (fig. 2).
  • Very suitable pro-enzymes for this principle are pro-enzymes of the serine protease family and particularly pro-urokinase.
  • pro-urokinase Assays have been developed for many matrix-metalloproteases (MMPs), Granzyme B,-various Cathepsins etc. Due to the involvement of a two stage reaction very sensitive assays have been developed measuring in the ng/ml or even pg/ml level.
  • MMPs matrix-metalloproteases
  • Granzyme B Granzyme B
  • Cathepsins a two stage reaction
  • the first set of pro-urokinase based substrates was obtained by replacing typically 4 amino-acid residues N-terminal to the activation site by a 4 residue recognition sequence recognizable and cleavable by the target protease. This approach worked well for many proteases such as MMPs, Granzyme B and Cathepsins.
  • serine proteases as detection enzyme has certain advantages such as easy detection of the activated enzyme, stability of the pro-enzyme and the availability of many possible candidate enzymes enabling optimization for special purposes.
  • One major limitation was discovered, the amino acid sequence in the C-terminal part of the cleavage site cannot be chosen freely but has limitations based on structural and mechanistic constraints tightly linked to the serine proteases. Due to these limitations the development of efficient substrates for a number of interesting proteases proved elusive.
  • the invention provides an improved method of determining a protease, or its precursor after activation, comprising incubating a sample with a target of said protease, determining proteolytic cleavage of said target, and correlating data obtained therefrom in order to determine the protease, wherein said target is a modified pro-caspase containing an activation site which is cleavable by said protease.
  • the proteolytic cleavage of said modified pro-caspase activates the pro-caspase and the resulting activity is determined using a suitable substrate of the activated pro-caspase.
  • the sample can be selected from the group consisting of a biological fluid, a fraction thereof, a biological tissue, an extract thereof, a fraction of said extract, a culture medium conditioned by in vitro or in vivo growing cells, tissues, or organisms, an extract of such a culture medium, and a fraction of such a culture medium.
  • the organisms and/or cells can be of any origin, such as viruses, bacteria, fungi (including yeast) and animals.
  • the invention is very well applicable with samples derived from mammalians, especially humans, e.g. from body fluids or cell extracts.
  • the protease to be assayed can be any protease, but preferably the protease is selected from the group consisting of serine proteases, cysteine proteases, aspartyl proteases and metalloproteases and more preferably it is selected from the group consisting of aggrecanase (ADAM TS4), ADAM TS1, TACE (ADAM-17), , BACE 1, BACE 2, HIV protease and hepatitis C protease.
  • ADAM TS4 aggrecanase
  • ADAM TS1 ADAM TS1
  • TACE ADAM-17
  • BACE 1 BACE 2
  • HIV protease hepatitis C protease
  • the modified pro-caspase can be derived from a pro-caspase by replacing its activation site by an activation site which is cleavable by the protease to be determined, such as by removing its activation site and inserting, not necessarily on the same position, an activation site which is cleavable by the protease to be determined.
  • the modified pro-caspase is derived from pro-caspase by altering its activation site rendering it inactive for its natural substrate and inserting, not necessarily on the same position, an activation site which is cleavable by the protease to be determined.
  • the modified pro-caspase is preferably selected from the group consisting of pro-caspase-1, pro-caspase-3, pro-caspase-7, pro-caspase-8, pro-caspase-9, and pro-caspase-10.
  • One embodiment of the invention which is particularly useful is a method wherein said modified pro-caspase is pro-caspase-3 or pro-caspase-7 and wherein said modification in pro-caspase-3 or pro-caspase- 7 is a replacement of D175 in wild-type pro-caspase-3 or D198 in wild-type pro-caspase-7 by a sequence selected from the group of sequences similar to the aggrecanase recognition sequence from aggrecan (GSDMELPLPRNITEGE ⁇ ARGSVILTVKPIFEEF), the TACE recognition sequence from TNF ⁇ (GSPLAQA ⁇ VRSSSRSG) or the BACE recognition sequence from ⁇ -amyloid precursor protein (GSKTEEISEVNL ⁇ DAEFRHDS) where the ⁇ symbol indicates the cleavage site in the physiological target.
  • GSDMELPLPRNITEGE ⁇ ARGSVILTVKPIFEEF the TACE recognition sequence from TNF ⁇
  • GSKTEEISEVNL ⁇ DAEFRHDS BACE recognition sequence from ⁇ -amy
  • the caspase substrate is a compound which comprises an amino acid sequence which is cleavable by caspase and which further has a part that can be easily detected after cleavage. Examples of such substrates are summarized in Table IV and sequences of some known caspase substrates are shown in Table V.
  • Preferably used is a compound comprising the amino acid sequence AspGluValAsp-pNA, in which pNA is p-nitro-anilide.
  • the invention also provides the modified pro-caspase per se, more particularly a modified pro-caspase derived from a pro-caspase by replacing its natural activation site or replacing an amino acid sequence in the region of its natural activation site by a modified activation site which is cleavable by a protease different from the one which activates the unmodified pro-caspase, or alternatively to insert such a modified activation site in the natural sequence of the pro-caspase.
  • the modified pro-caspase is derived from pro-caspase-3 or pro-caspase-7.
  • the invention further provides a kit for determining a protease, or its precursor after activation, in a sample, comprising a modified pro-caspase as defined herein, together with the normal constituents of such a kit, such as substrates for activated pro-caspase, buffer solutions, standard preparations, detergents, specific antibodies, microtiterplates and instructions for use.
  • the invention provides a device for determining a protease or its precursor after activation, in a sample, comprising a modified pro-caspase as defined herein.
  • the invention can be used to determine catalytically active proteases involved in biotechnologically or (patho) physiologically interesting processes.
  • Determining a protease means both qualitative analysis, i.e. detecting the presence of the protease, particularly its activity, and quantitative analysis, i.e. quantifying the protease activity present in a sample.
  • proteases examples include proteases with established clinical or biotechnological relevance, as well as proteases which could be involved in relevant (patho) physiological processes based on current knowledge.
  • the invention discloses methods suitable to assay members of all four known protease families, serine proteases, cysteine proteases, metalloproteases and aspartyl proteases.
  • the invention discloses methods to assay proteases with any target recognition sequence.
  • proteases do not occur in biological fluids in the catalytically active form but in an inactive zymogen or pro-enzyme form. In such cases conversion to the active form is required before measurement.
  • conversion to the active protease can be accomplished by limited proteolytic digestion, treatment with certain chemicals or mild denaturation by application of heat or e.g. sodium dodecylsulphate.
  • Methods based on the invention can be very sensitive and specific and can easily be adapted for automation using generally available laboratory equipment. The invention appears to be most applicable in biotechnology, animal or human health research laboratories and hospitals and clinical laboratories and pharmaceutical research laboratories. Other applications might be in quality control in pharmaceutical or food-processing industries.
  • the invention uses a pro-enzyme as target substrate for the protease which needs to be assayed which can be converted to an active enzyme by one or more specific proteolytic events and subsequently the activity of the active enzyme is detected using standard technology known in the art (Fig.2). More particularly the invention relates to the choice of the pro-enzyme.
  • a pro-enzyme as target substrate for the protease which needs to be assayed which can be converted to an active enzyme by one or more specific proteolytic events and subsequently the activity of the active enzyme is detected using standard technology known in the art (Fig.2). More particularly the invention relates to the choice of the pro-enzyme.
  • pro-enzymes can be chosen as a basis for modification and development of an assay for a particular protease, most pro-enzymes have certain limitations in the sequence that can be modified and consequently the proteases that can be measured.
  • Pro-caspases are a family of cysteine protease pro-enzymes which are involved in apoptosis, regulated cell death (Fig. 5).
  • the caspases form a cascade in which one active caspase can activate an (other) pro-caspase leading to a chain of reactions in the cell resulting in cell death.
  • Caspases are very specific proteases. They recognize sequences with several negatively charged amino acid residues like Glu or Asp and cleave C-terminal of such sequences.
  • Typical recognition sequences within the caspase family are summarized in table IV.
  • Each member of the caspase family has a certain preference for a certain sequence although there is considerable overlap with the substrate sequence of other caspases.
  • the activation sequence of many if not all pro-caspases is a sequence that itself can be cleaved by one or more active caspases. Due to their involvement in apoptosis, a process likely involved in many diseases such as e.g. cancer, a large number of peptide substrates cleavable by caspases and resulting in the liberation of a coloured or fluorescent group have been developed and are commercially available (table V).
  • the present invention also discloses modified pro-caspases which can be used to detect proteases hitherto not detectable with current methodology or with great difficulty or low efficiency.
  • the modification of the pro-caspase is such that the normal activation reaction by e.g. other caspase family members or auto-activation is prevented. This can be accomplished by alteration or even complete removal of the normal activation sequence.
  • the novel target activation sequence recognizable and cleavable by the protease of choice, can replace the normal activation sequence but can also be introduced elsewhere in the pro-caspase sequence.
  • the site for insertion of a target sequence is not critical, although care should be taken that cleavage of the modified pro-caspase still results in formation of an active caspase. Again, checking if such activity is retained and adapting the insertion site, is well within the realm of the skilled person.
  • Secondary modifications could be included, directed at improving the properties of the pro-caspase or caspase formed after activation for the particular application.
  • Useful secondary modifications include: modifications increasing the (thermal) stability of the pro-caspase or activated caspase, conferring resistance to other, non-target, proteases, conferring resistance to naturally occurring or synthetic inhibitors, conferring reactivity to certain antibodies or ligands, aiding expression and/or purification or alterations increasing activity of the activated form or decreasing activity of the pro-form.
  • such secondary mutations will be in another part of the caspase and not near the activation site. It is also possible to introduce more than one novel activation site, thus resulting in a target substrate that can be used for a variety of proteases with different substrate specificity.
  • caspase-3 and caspase-7 are very suitable since these two caspases are very stable and easy to produce by existing methodology. Also it appears that activation of pro-caspase-3 and -7 is critically dependent on proteolytic cleavage in the activation region.
  • substrates for these caspases exist (table V). For detection of the caspase activity, these substrates should have amino acid sequences that are recognised and cleaved by the caspase which is used in the test (table V shows a number of known sequences and the recognising caspases). Most preferably used is the amino acid sequence DEVD (asp-glu-val-asp).
  • the cleaved substrate should yield a signal for detection.
  • This can, for instance, be achieved by linking para-nitro-anilide, 7-amino-4-trifluoro methyl coumarine, amino methyl coumarine or any other color, fluorescence or luminescence generating compound directly to the C-terminus of the peptide sequence which is recognised by the caspase. Then these compounds will become free in the test solution as a result of caspase action and the presence of these compounds can quantitatively be detected e.g. by spectrophotometry, fluorimetry or luminometry.
  • a cDNA sequence coding for a particular pro-caspase must be available. Such sequences are known and can be obtained from publicly available databases. Such a cDNA can be obtained with existing technology such as from mRNA isolated from a suitable cell line or tissue by reverse transcriptase polymerase chain reaction using primers devised with the aid of the known sequence. Many alternative procedures are known in the art to obtain a specific cDNA sequence.
  • the coding sequence can be adapted to improve later expression into protein and to facilitate later introduction of changes aimed at altering the activation specificity of the resulting pro-caspase after expression. Also a suitable promoter and other regulatory sequences have to be added as is known in the art.
  • the coding sequence or altered coding sequence is introduced into a vector such as a plasmid or virus to enable introduction into a cell system for expression. Expression can in general be performed in eukaryotic animal cell or yeast expression systems or in prokaryotic bacterial expression systems. These systems are known in the art and are in many cases available in commercial form. After the expression step procedures to free the expressed protein from the cells or isolate it from the culture medium are generally required. Very likely further purification of the expressed protein will be required. Many procedures for these steps are known in the art.
  • a further advantage of this approach employing newly introduced restriction sites and subsequent oligo insertion, is the lower chance on secondary unwanted mutations that might arise during polymerase chain reaction based methods.
  • Such a modified pro-caspase can be part of an assay kit containing all necessary materials to perform one or a number of determinations.
  • such a kit comprises containers with sufficient quantities of modified pro-caspase, a suitable substrate to detect caspase activity, a suitable standard preparation to quantify the protease to be measured and materials to prepare buffer solutions.
  • kits might also contain specific antibodies recognizing the protease to be assayed to increase the specificity of the assay by specific quenching of the activity of a specific protease, interfering protease or specific binding of a protease.
  • a kit might also contain one or more assay plates in e.g. the regular 96-well, 384-well or 1536-well format.
  • stabilizers could be other proteins like albumin or gelatin, carbohydrates like mannitol, anti oxidants, detergents or other organic chemicals.
  • inorganic salts might also have beneficial effects on stability.
  • the modified pro-caspase is present in lyophylized form and has to be reconstituted by adding buffer or water shortly before use.
  • a description how to perform the determination, preparing the samples and calculate the activity is included.
  • Another possibility to increase the specificity as known in the art is to employ an immunocapture procedure: first the protease to be measured is caught using a specific immobilized (mono- or polyclonal) antibody followed by measurement of the activity of the caught protease.
  • a kit or device might be of the "dipstick" type where all necessary reagents present in a dry form are immobilized on a strip or dot of material.
  • Pro-enzymes of the serine protease family such as pro-urokinase have a number of suitable properties for their use as detection enzymes to measure the activity of proteases:
  • the active form of the serine proteaes is easily measured with chromogenic or fluorogenic peptide substrates; the difference in activity between pro-enzyme and active enzyme is generally high; the enzymes are generally stable and can be very specific.
  • a major drawback of using serine-protease family members as detection enzyme are the sequence limitations in the C-terminal part of the activation sequence.
  • the newly formed N-terminus that results from cleavage of the activation sequence plays an essential role in generation of the active enzyme. Comparison of these sequences from a number of serine-proteases family members (table II) reveals a strong homology in this region suggesting an involvement in the function. The flexibility in sequence in this region was in more detail investigated for pro-urokinase.
  • the complete cDNA coding for human pro-urokinase was cloned into an expression vector enabling expression of the protein in eukaryotic cells ( EP 691 409 ).
  • the oligonucleotide pairs used for construction of the various expression plasmids are summarised in Table VI.
  • the newly constructed plasmids were transfected into CHO cells and medium from the transiently transfected cells was collected. Concentrations of pro-urokinase variants in the conditioned media were determined by an ELISA recognising the protease domain of the molecule, thus ensuring a similar response for all variants.
  • Pro-urokinase variants were immuno-captured to a plate coated with antibody recognizing both pro-urokinase and active urokinase and not inhibiting the activity of the latter or interfering with the conversion of the pro-enzyme form to the active form.
  • a cDNA coding for caspase-3 cloned into an expression vector having a sequence coding for a His-tag enabling rapid purification using Ni chelate chromatography and regulatory sequences enabling expression in E . coli was obtained from the ATCC .
  • This plasmid was used as a basis for construction of similar plasmids coding for a variety of caspase-3 variants with modifications in their activation sequence.
  • two new silent restriction sites were introduced by PCR (fig. 7a). After digestion with BamHI and EcoRI a novel coding sequence can be introduced using two oligonucleotides .
  • the supernatant was brought on a nickel Sepharose (Amersham Biosciences) column (2 ml column volume for 30-50 ml of original culture volume) and subsequently washed with 20 column volumes of 50 mM TrisHCl pH 8.0, 300 mM NaCl, 20 mM imidazol, (wash buffer) and eluted with elution buffer (50 mM TrisHCl pH 8.0, 300 mM NaCl, 250 mM imidazol).
  • the peak fractions were desalted using a PD-10 column (Amersham Biosciences) equilibrated with 10 mM Tris HCl pH 7.0, 1.5 mM NaCl, 0.01% (v/v) BRIJ 35 buffer (Fig. 8).
  • cDNA and expression vectors coding for variants of pro-caspase-7 were constructed containing sequences coding for pro-caspase-7 variants with activation sequences for TACE and aggrecanase.
  • the oligonucleotides to introduce the novel activation sequences were exactly the same as used for pro-caspase-3 variants (see Table VII). Transformation, expression and purification of pro-caspase-7 variants was performed as described for pro-caspase-3 variants in example 2.
  • Protocol for detection of aggrecanase activity using pro-caspase-3 or -7 variants with an aggrecanase cleavable activation sequence (see Example 2 and Table VII).
  • the detection is performed in two steps, in the first step the pro-caspase variant is incubated with its target enzyme and in the second step the amount of pro-caspase variant converted to active caspase variant is detected by incubation with a caspase substrate.
  • Wells of a 96-well microtiter plate were filled with 10 ⁇ l (1-100 ng) of pro-caspase-3 or -7 variant and 60 ⁇ l assay buffer (50 mM TrisHCl, 1.5 mM NaCl, 0.5 mM CaCl2, 1 ⁇ M ZnCl 2 0.01% (v/v) BRIJ35). 10 ⁇ l aggrecanase diluted in assay buffer as indicated was added. After incubation at 37°C overnight 10 ⁇ l of 100 mM DTT and 10 ⁇ l of 8 mM DEVD-pNA (BioSource) in H 2 O were added.
  • the plate was incubated at 37°C in a moist chamber for 0-6h, and A405 was measured after regular intervals using a Titertek Multiskan plate reader. For each enzyme concentration the absorbance change was plot against incubation time (Fig. 10a). The slopes of these curves were plot against aggrecanase concentration (Fig. 10b).
  • a pro-caspase-3 variant was produced containing a sequence cleavable by ⁇ -amyloid converting enzyme (BACE-1) (see Table VII and Fig 7 a,b).
  • BACE-1 ⁇ -amyloid converting enzyme
  • 10 ⁇ l of purified modified caspase-3 with a BACE-1 specific cleavage was mixed with 300 ⁇ l 10 mM Na-acetate pH 5.1, 1.5 mM NaCl, 0.01% (v/v) BRIJ35 and 10 ⁇ l BACE-1 enzyme.
  • an immuno-capture format In such a format the protease to be detected, generally present in a biological sample at low concentration in the presence of a variety of disturbing compounds such as salts, other proteases, protease inhibitors etc., is specifically removed from the biological sample using e.g. a microtiter plate coated with an antibody specifically recognizing and binding the target protease. After binding of the target protease to the plate the sample containing the interfering substances is removed and the plate can be washed if required and a clearly defined solution with purified components can be added.
  • a microtiter plate coated with an antibody specifically recognizing and binding the target protease After binding of the target protease to the plate the sample containing the interfering substances is removed and the plate can be washed if required and a clearly defined solution with purified components can be added.
  • Such an approach has several advantages and is frequently used for the detection of closely related proteases with overlapping substrate specificity such as the MMP family of proteases.
  • a microtiter plate (Costar EIA/RIA 8 well flat bottom) is coated with 100 ⁇ l per well of 10 ⁇ g/ml goat-anti-mouse IgG and 2 ⁇ g/ml mouse monoclonal antibody recognizing TACE overnight at 4°C in Na-carbonate buffer pH 9.6. After washing 4 times with 0.01 M Na-phosphate pH 7.0, 0.15 M NaCl, 0.05 % (v/v), the plate is used as an immuno-capture plate. Samples containing TACE are pipetted into the plate and incubated at 4°C overnight.
  • pro-enzymes of the serine protease family Proenzyme Bond split upon activation P 4 - P 3 - P 2 - P 1 ⁇ P' 1 -P' 2 -P' 3 -P' 4 Prothrombin Glu-Gly-Arg ⁇ Ile-Val-Glu-Gly Pro-urokinase Arg-Phe-Lys ⁇ Ile-Ile-Gly-Gly trypsinogen Asp-Asp-Lys ⁇ Ile-Val-Gly-Gly chymotrypsinogen Leu-Ser-Arg Ile-Val-Asn-Gly Pro-elastase Val-Tyr-Arg ⁇ Val-Val-Gly-Glu Pro-subtilisin Ala-Gly-Lys ⁇ Ser-Asn-Gly-Glu Coagulation factor V Gly-Ile-Arg ⁇ Ser-Phe-Arg-Phe Coagulation factor VII Pro-Gln-Arg ⁇
  • Peptide substrates for detection of caspase activity Substrate Preferred caspase VAD-X 1 DEVD-X 3, 6, 7, 8 VEID-X 6, 8 IETD-X 8, 9, 10 WEHD-X 1, 4, 5 YVAD-X 1,4,5 VDVAD-X 2 X can be -pNA (para-nitro-anilide), -AFC (7-amino-4 trifluoro methyl coumarine), -AMC (amino methyl coumarine), or any other chromogenic or fluorogenic leaving group.
  • Table VII Oligonucleotide cassettes used for construction of modified-caspase expression vectors Aggrecanase (ADAMTS4) TACE (TNF ⁇ converting enzyme) BACE ( ⁇ -amyloid converting enzyme)
  • oligonucleotide pairs were ligated into BamHl and EcoRl cut pro-caspase-3 or pro-caspase-7 expression vector to obtain expression vectors coding for pro-caspase variants with cleavage/activation sites for ADAMTS4, TACE and BACE. Recognition sequences of the proteins are indicated in bold above the oligonucleotides, cleavage sites are indicated with an ⁇ . See also figure 7.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Claims (15)

  1. Verfahren zur Bestimmung einer Protease oder ihres Vorläufers nach der Aktivierung, bei dem man eine Probe mit einem Ziel dieser Protease inkubiert, die proteolytische Spaltung des Ziels bestimmt und die daraus erhaltenen Daten korreliert, um die Protease zu bestimmen, wobei das Ziel eine modifizierte Pro-Kaspase ist, die eine Aktivierungsstelle umfasst, welche von einer Protease spaltbar ist.
  2. Verfahren nach Anspruch 1, bei dem die proteolytische Spaltung der modifizierten Pro-Kaspase die Pro-Kaspase aktiviert und bei dem die resultierende Aktivität unter Verwendung eines geeigneten Substrats der aktivierten Pro-Kaspase bestimmt wird.
  3. Verfahren nach Anspruch 1 oder 2, bei dem die Probe ausgewählt aus der Gruppe bestehend aus einer biologischen Flüssigkeit, einer Fraktion derselben, einem biologischen Gewebe, einem Extrakt desselben, einer Fraktion eines solchen Extrakts, einem Kulturmedium, das durch in vitro wachsende Zellen, Gewebe oder Organismen konditioniert ist, einem Extrakt eines solchen Kulturmediums und einer Fraktion eines solchen Kulturmediums.
  4. Verfahren nach einem der vorhergehenden Ansprüche, bei dem die Protease ausgewählt ist aus der Gruppe bestehend aus Serinproteasen, Cysteinproteasen, Aspartylproteasen und Metalloproteasen.
  5. Verfahren nach Anspruch 4, bei dem die Protease ausgewählt ist aus der Gruppe bestehend aus Aggrecanase, ADAM TS1, ADAM TS4, TACE, BACE, BACE 1, BACE 2, HIV-Protease und Hepatitis C-Protease.
  6. Verfahren nach einem der vorhergehenden Ansprüche, bei dem die modifizierte Pro-Kaspase aus einer Pro-Kaspase abgeleitet wird, indem die Aktivierungsstelle durch eine Aktivierungsstelle ersetzt wird, die von der zu bestimmenden Protease spaltbar ist.
  7. Verfahren nach einem der vorhergehenden Ansprüche, bei dem die modifizierte Pro-Kaspase von einer Pro-Kaspase abgeleitet wird, indem die Aktivierungsstelle entfernt wird und (nicht notwendigerweise an der gleichen Position) eine Aktivierungsstelle eingesetzt wird, die von der zu bestimmenden Protease spaltbar ist.
  8. Verfahren nach einem der Ansprüche 6 oder 7, bei dem die modifizierte Pro-Kaspase von einer Pro-Kaspase abgeleitet wird, indem ihre Aktivierungsstelle verändert wird, so dass diese in Bezug auf ihr natürliches Substrat inaktiv ist, und (nicht notwendigerweise an der gleichen Position) eine Aktivierungsstelle eingesetzt wird, die von der zu bestimmenden Protease spaltbar ist.
  9. Verfahren nach einem der vorhergehenden Ansprüche, bei die modifizierte Pro-Kaspase ausgewählt ist aus der Gruppe bestehend aus Pro-Kaspase-1, Pro-Kaspase-3, Pro-Kaspase-7, Pro-Kaspase-8, Pro-Kaspase-9 und Pro-Kaspase-10.
  10. Verfahren nach Anspruch 9, bei dem die modifizierte Pro-Kaspase eine Pro-Kaspase-3 oder eine Pro-Kaspase-7 ist, und bei dem die Modifikation in der Pro-Kaspase-3 oder in der Pro-Kaspase-7 ein Ersetzen von D175 in der Wildtyp-Pro-Kaspase-3 oder von D198 in der Wildtyp-Pro-Kaspase-7 durch eine Sequenz ist, die ausgewählt ist aus der Gruppe der Sequenzen GSDMELPLPRNITEGE^ARGSVILTVKPIFEEF, GSPLAQA^VRSSSRSG und GSKTEEISEVNL^DAEFRHDS, wobei das Symbol ^ die Schnittstelle in dem physiologischen Ziel bezeichnet.
  11. Verfahren nach einem der Ansprüche 2 bis 10, wobei das Kaspase-Substrat eine Verbindung ist, welche die Aminosäuresequenz AspGluValAsp-pNA umfasst, wobei pNA p-Nitroanilid ist.
  12. Modifizierte Pro-Kaspase, die von einer Pro-Kaspase abgeleitet wird, indem sie mit einer Erkennungsstelle ausgestattet wird, die von einer Protease spaltbar ist, welche sich von der unterscheidet, die die unmodifizierte Pro-Kaspase spaltet und aktiviert.
  13. Modifizierte Pro-Kaspase nach Anspruch 12, bei der die Erkennungsstelle eine Aktivierungsstelle ist, die von einer Protease spaltbar ist, welche sich von der unterscheidet, die die unmodifizierte Pro-Kaspase aktiviert, wobei die Aktivierungsstelle die originale Aktivierungsstelle der Pro-Kaspase ersetzt.
  14. Modifizierte Pro-Kaspase nach Anspruch 13, die von Pro-Kaspase-3 oder von Pro-Kaspase-7 abgeleitet ist.
  15. Kit zur Bestimmung einer Protease oder ihres Vorläufers nach der Aktivierung in einer Probe, das eine modifizierte Pro-Kaspase nach den Ansprüchen 12 bis 14 umfasst.
EP04706386A 2003-01-31 2004-01-29 Verbessertes verfahren zum nachweis von proteolytischen enzymen Expired - Lifetime EP1587952B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04706386A EP1587952B1 (de) 2003-01-31 2004-01-29 Verbessertes verfahren zum nachweis von proteolytischen enzymen

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03075319 2003-01-31
EP03075319A EP1443116A1 (de) 2003-01-31 2003-01-31 Verbessertes Verfahren zum Nachweis von proteolytischen Enzymen
EP04706386A EP1587952B1 (de) 2003-01-31 2004-01-29 Verbessertes verfahren zum nachweis von proteolytischen enzymen
PCT/NL2004/000067 WO2004067768A2 (en) 2003-01-31 2004-01-29 Improved method for the detection of proteolytic enzymes

Publications (2)

Publication Number Publication Date
EP1587952A2 EP1587952A2 (de) 2005-10-26
EP1587952B1 true EP1587952B1 (de) 2007-09-19

Family

ID=32605369

Family Applications (2)

Application Number Title Priority Date Filing Date
EP03075319A Withdrawn EP1443116A1 (de) 2003-01-31 2003-01-31 Verbessertes Verfahren zum Nachweis von proteolytischen Enzymen
EP04706386A Expired - Lifetime EP1587952B1 (de) 2003-01-31 2004-01-29 Verbessertes verfahren zum nachweis von proteolytischen enzymen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP03075319A Withdrawn EP1443116A1 (de) 2003-01-31 2003-01-31 Verbessertes Verfahren zum Nachweis von proteolytischen Enzymen

Country Status (6)

Country Link
US (2) US7361485B2 (de)
EP (2) EP1443116A1 (de)
JP (1) JP4708326B2 (de)
AT (1) ATE373723T1 (de)
DE (1) DE602004009036T2 (de)
WO (1) WO2004067768A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005015756D1 (de) * 2004-12-23 2009-09-10 Tno Verfahren zum funktionellen nachweis von masps und dessen komplexen
WO2007091881A2 (en) * 2005-04-29 2007-08-16 Leiden University Medical Center Methods and means for detection of mycobacterium leprae infections
JP5965925B2 (ja) * 2011-03-11 2016-08-10 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー ボツリヌス神経毒生物活性の決定のための方法
US9402876B2 (en) 2013-11-27 2016-08-02 Industrial Technology Research Institute Method and pharmaceutical composition for hair growth
CA3229467A1 (en) * 2021-09-02 2023-03-09 Wei Chen Multiplex, temporally resolved molecular signal recorder and related methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0691409B1 (de) * 1994-07-07 2002-10-23 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Modifizierte Proenzyme als Substrate für proteolische Enzyme
DE69528614T2 (de) * 1994-07-07 2003-06-18 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno, Delft Modifizierte Proenzyme als Substrate für proteolische Enzyme
US6270980B1 (en) * 1997-06-05 2001-08-07 Idun Pharmaceuticals, Inc. Rapid methods for identifying modifiers of cellular apoptosis activity
US6379950B1 (en) * 1998-01-09 2002-04-30 Thomas Jefferson University Recombinant, active caspases and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
JP2006516900A (ja) 2006-07-13
DE602004009036D1 (de) 2007-10-31
EP1587952A2 (de) 2005-10-26
US7361485B2 (en) 2008-04-22
US20080187945A1 (en) 2008-08-07
ATE373723T1 (de) 2007-10-15
DE602004009036T2 (de) 2008-06-19
EP1443116A1 (de) 2004-08-04
WO2004067768A2 (en) 2004-08-12
US20060240406A1 (en) 2006-10-26
JP4708326B2 (ja) 2011-06-22
WO2004067768A3 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
US5811252A (en) Modified proenzymes as substrates for proteolytic enzymes
Stennicke et al. Caspases: preparation and characterization
Uría et al. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity
Verheijen et al. Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase
EP2895859B1 (de) Proteasebasiertes biosensormolekül
Stennicke et al. Caspase assays
US20060269538A1 (en) Serine proteases with altered sensitivity to activity-modulating substances
Hedstrom An overview of serine proteases
US20080187945A1 (en) Method for the detection of proteolytic enzymes
Rajapakse et al. Biochemical characterization of human kallikrein 8 and its possible involvement in the degradation of extracellular matrix proteins
Goossens et al. The Purification, Characterization and Analysis of Primary and Secondary‐Structure of Prolyl Oligopeptidase from Human Lymphocytes: Evidence that the Enzyme Belongs to the α/β Hydrolase Fold Family
Nagase Metalloproteases
Kishi et al. Activation and enzymatic characterization of recombinant human kallikrein 8
Stafslien et al. Characterization of the streptococcal C5a peptidase using a C5a-green fluorescent protein fusion protein substrate
US20060134740A1 (en) Engineered proteases for affinity purification and processing of fusion proteins
Dostál et al. The precursor of secreted aspartic proteinase Sapp1p from Candida parapsilosis can be activated both autocatalytically and by a membrane-bound processing proteinase
EP0691409B1 (de) Modifizierte Proenzyme als Substrate für proteolische Enzyme
WO2020200315A1 (zh) 经修饰的苯丙氨酸氧化酶酶原及其用途
WO2005071100A2 (en) Method for determination of protein modifying or demodifying activity and suitable materials thereof
Deo et al. Bioluminescence detection of proteolytic bond cleavage by using recombinant aequorin
Kannan et al. Purification of active matrix metalloproteinase catalytic domains and its use for screening of specific stromelysin-3 inhibitors
Fu et al. Cloning, expression, purification, and characterization of rat MMP-12
Okubo et al. Processing, catalytic activity and crystal structures of kumamolisin‐As with an engineered active site
Lam et al. Isolation and characterisation of two chymotrypsins from the midgut of Locusta migratoria
Wildeboer et al. Characterization of bacterial proteases with a panel of fluorescent peptide substrates

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050815

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20060901

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 602004009036

Country of ref document: DE

Date of ref document: 20071031

Kind code of ref document: P

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATENTANWAELTE SCHAAD, BALASS, MENZL & PARTNER AG

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070919

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071220

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071230

EN Fr: translation not filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070919

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070919

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070919

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070919

26N No opposition filed

Effective date: 20080620

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080523

ET Fr: translation filed
REG Reference to a national code

Ref country code: FR

Ref legal event code: EERR

Free format text: CORRECTION DE BOPI 08/21 - BREVETS EUROPEENS DONT LA TRADUCTION N A PAS ETE REMISE A L INPI. IL Y A LIEU DE SUPPRIMER : LA MENTION DE LA NON-REMISE. LA REMISE DE LA TRADUCTION EST PUBLIEE DANS LE PRESENT BOPI.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070919

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070919

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070919

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080129

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080320

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070919

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080131

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20140128

Year of fee payment: 11

Ref country code: BE

Payment date: 20140121

Year of fee payment: 11

Ref country code: CH

Payment date: 20140121

Year of fee payment: 11

Ref country code: SE

Payment date: 20140121

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20140113

Year of fee payment: 11

Ref country code: FR

Payment date: 20140123

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150131

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 373723

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150131

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150131

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20150930

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150129

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150202

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150129

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230119

Year of fee payment: 20

Ref country code: DE

Payment date: 20230123

Year of fee payment: 20

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230522

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230119

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 602004009036

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20240128

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20240128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240128